A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient
Clinical Psychopharmacology and Neuroscience – May 21, 2024
Source: OpenAlex
Summary
While Psilocybin shows promise as a medicine, a compelling case highlights its risks: one patient with depression, personality traits, and cannabis use developed psychosis, catatonia, and suicidality after months of heavy Psilocybin use. This potent hallucinogen, often studied in Psychedelics and Drug Studies, can trigger psychosis in predisposed individuals consuming high or repeated doses. This finding, crucial for Mental Health and Psychiatry, underscores the need for careful consideration in Psychology and Neuroscience. Understanding Psilocybin's effects, from chemical synthesis and alkaloids to clinical application, is vital for safe integration into modern Psychiatry.
Abstract
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Individuals with risk factors for psychosis are typically excluded from such studies, limiting the empiric research of the risks and benefits in vulnerable populations. In the real-world setting, many individuals who seek treatment with psilocybin will have comorbid psychiatric conditions and other factors that predispose them to psychosis. We report a case of a patient with multiple predisposing risk factors, including a history of depression, personality disorder traits, and cannabis use, who experienced a psychotic episode with catatonic features and suicidality after several months of heavy psilocybin use. A review of similar previously published case reports demonstrates a pattern of psilocybin-induced psychosis occurring primarily in individuals with predisposing factors who have consumed either high or repeated doses of the drug. This case report furthers this pattern, which serves as both a warning that psilocybin use is not without risks and reassurance for researchers using much lower doses to treat mental illness.